Skip to main content

Table 2 Mixed effects linear regression model fitting assessment of association of chemotherapy type with chromosome-specific telomere length

From: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study

Chromosome arm

Least square mean

p value

 

TAC1

TC

TCH

FDR

1p

4.346 (0.251)*

2.944 (0.451)

2.813 (0.501)

0.004

0.048

1q

5.642 (0.314)

4.016 (0.564)

4.433 (0.626)

0.028

0.056

2p

5.602 (0.315)

3.929 (0.565)

4.174 (0.628)

0.017

0.048

2q

4.247 (0.263)

3.125 (0.473)

3.486 (0.526)

0.094

0.101

3p

6.252 (0.319)

4.671 (0.574)

5.508 (0.637)

0.059

0.075

3q

5.488 (0.317)

3.853 (0.570)

4.051 (0.634)

0.020

0.048

4p

4.475 (0.280)

3.671 (0.502)

3.436 (0.558)

0.157

0.160

4q

5.876 (0.326)

4.425 (0.586)

4.689 (0.651)

0.059

0.075

5p

5.451 (0.295)

3.696 (0.531)

4.376 (0.589)

0.014

0.048

5q

4.590 (0.309)

3.682 (0.556)

3.714 (0.618)

0.064

0.080

6p

5.698 (0.298)

4.028 (0.536)

4.417 (0.596)

0.015

0.048

6q

5.383 (0.312)

3.835 (0.561)

4.279 (0.623)

0.039

0.064

7p

4.598 (0.269)

3.465 (0.484)

3.383 (0.538)

0.043

0.066

7q

5.335 (0.305)

3.673 (0.549)

4.163 (0.609)

0.022

0.050

8p

5.453 (0.288)

3.821 (0.518)

4.301 (0.575)

0.016

0.048

8q

4.685 (0.312)

3.252 (0.561)

3.593 (0.623)

0.056

0.075

9p

5.664 (0.314)

4.201 (0.564)

4.304 (0.627)

0.034

0.058

9q

4.037 (0.259)

2.581 (0.465)

2.821 (0.517)

0.012

0.048

10p

5.729 (0.313)

4.114 (0.562)

4.107 (0.624)

0.013

0.048

10q

4.821 (0.299)

3.726 (0.537)

3.531 (0.597)

0.070

0.083

11p

4.791 (0.292)

3.639 (0.524)

3.758 (0.582)

0.090

0.099

11q

5.413 (0.327)

4.152 (0.587)

3.837 (0.653)

0.045

0.067

12p

4.890 (0.287)

3.289 (0.515)

3.918 (0.572)

0.023

0.050

12q

4.838 (0.289)

3.674 (0.520)

3.791 (0.578)

0.083

0.093

13p

5.093 (0.289)

3.422 (0.519)

4.096 (0.576)

0.018

0.048

13q

5.599 (0.323)

4.146 (0.580)

4.111 (0.645)

0.033

0.058

14p

5.221 (0.314)

3.349 (0.565)

3.864 (0.628)

0.010

0.048

14q

5.000 (0.312)

3.487 (0.561)

3.856 (0.623)

0.041

0.065

15p

4.885 (0.285)

3.131 (0.512)

3.896 (0.569)

0.012

0.048

15q

5.535 (0.318)

3.823 (0.571)

4.112 (0.634)

0.017

0.048

16p

4.064 (0.237)

2.993 (0.426)

3.137 (0.473)

0.049

0.070

16q

4.614 (0.281)

3.126 (0.504)

3.398 (0.560)

0.020

0.048

17p

4.282 (0.250)

3.083 (0.449)

4.464 (0.499)

0.051

0.071

17q

4.265 (0.276)

3.126 (0.496)

3.507 (0.551)

0.110

0.115

18p

5.224 (0.322)

4.218 (0.578)

4.404 (0.643)

0.238

0.238

18q

5.556 (0.292)

4.058 (0.526)

4.310 (0.584)

0.024

0.050

19p

4.281 (0.248)

2.280 (0.445)

3.185 (0.495)

0.010

0.048

19q

4.852 (0.261)

3.232 (0.469)

3.786 (0.522)

0.009

0.048

20p

5.054 (0.300)

3.684 (0.539)

4.122 (0.599)

0.067

0.081

20q

4.430 (0.262)

2.917 (0.470)

3.414 (0.522)

0.015

0.048

21p

5.356 (0.278)

3.474 (0.500)

4.242 (0.555)

0.005

0.048

21q

4.700 (0.257)

3.121 (0.462)

3.267 (0.513)

0.004

0.048

22p

5.068 (0.282)

3.438 (0.506)

3.995 (0.562)

0.016

0.048

22q

4.269 (0.264)

3.086 (0.475)

3.028 (0.527)

0.031

0.058

Xp

5.518 (0.322)

4.320 (0.579)

4.190 (0.643)

0.077

0.089

Xq

5.237 (0.316)

3.834 (0.567)

3.756 (0.630)

0.032

0.058

  1. *The standard error is shown in parenthesis; bold rows indicate values showing statistical significance using an FDR threshold
  2. 1TAC = sequential administration of docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (Cytoxan); TC = docetaxel (Taxotere) and cyclophosphamide (Cytoxan); TCH = docetaxel (Taxotere), Carboplatin (Paraplatin), and trastuzumab (Herceptin)